Evidence map›Paper›PMID 17876577›Full record

ReviewApplied microbiology and biotechnology2007

Assessment of technological options and economical feasibility for cyanophycin biopolymer and high-value amino acid production.

Hans Mooibroek, Nico Oosterhuis, Marco Giuseppin, Marcel Toonen, Henk Franssen, Elinor Scott, Johan Sanders, Alexander Steinbüchel

Open access · hybridAbstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Cyanophycin Modifications-Widening the Application Potential.Frontiers in bioengineering and biotechnology · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Solubility behavior of cyanophycin depending on lysine content.Applied and environmental microbiology · 2014
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Hans MooibroekWageningen University and Research Centre, , P.O. Box 17, NL-6700 AA, Wageningen, The Netherlands. hans.mooibroek@wur.nl
Nico Oosterhuis
Marco Giuseppin
Marcel Toonen
Henk Franssen
Elinor Scott
Johan Sanders
Alexander Steinbüchel
Wageningen University & Research · NLUniversity of Münster · DE

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

Major transitions can be expected within the next few decades aiming at the reduction of pollution and global warming and at energy saving measures. For these purposes, new sustainable biorefinery concepts will be needed that will replace the traditional mineral oil-based synthesis of specialty and bulk chemicals. An important group of these chemicals are those that comprise N-functionalities. Many plant components contained in biomass rest or waste stream fractions contain these N-functionalities in proteins and free amino acids that can be used as starting materials for the synthesis of biopolymers and chemicals. This paper describes the economic and technological feasibility for cyanophycin production by fermentation of the potato waste stream Protamylassetrade mark or directly in plants and its subsequent conversion to a number of N-containing bulk chemicals.

Indexed as

Amino AcidsBacteriaBacterial ProteinsBiopolymersBiotechnologyFermentationNicotianaPlant ProteinsSolanum tuberosumAmino AcidsBacterial ProteinsBiopolymerscyanophycinPlant Proteins

Identifiers

PMID17876577
PMCPMC2043089
OpenAlexW2072956254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.